NACDS is lauding legislation introduced by U.S. Senators Peter Welch (D-VT) and Roger Marshall (R-KS) to crack down on tactics by which “pharmaceutical benefit manipulator” middlemen maximize profits at the expense of patients, pharmacies, and others.
Statement defines specific solutions for patient-manipulation by “PBMs” and urges continued bipartisan work on this critical issue.
Last week, Health and Human Services (HHS) Secretary Xavier Becerra appeared before the U.S. Senate Appropriations Committee to provide testimony on the FY 2024 Funding Request and Budget Justification of the Department of Health and Human Services.
96 percent of those 65 and older say it is “very easy” or “somewhat easy” to access pharmacies – making them the most accessible healthcare destination tested in a national poll.
NACDS President and Chief Executive Officer Steven C. Anderson issued the following statement today upon passage of the Pharmacy Benefit Manager Transparency Act (S. 127) by the U.S. Senate Commerce, Science, and Transportation Committee:
Announces updated national, state, and Congressional District polling relevant to priority issues.
The Drug Price Transparency in Medicaid Act will protect patients, pharmacies, and others from middlemen tactics that drive up prescription drug prices.
Pharmacy benefit manager (PBM) reform; comprehensive direct and indirect remuneration (DIR) fee reform; and sustaining patient access to vaccinations, testing, and treatment among key topics at the February 28-March 1 program.
U.S. House Oversight and Accountability Committee expands bipartisan Congressional push to stop pharmaceutical benefit manipulation by middlemen.
Statement outlines specific solutions to patient-manipulation by “PBMs”.
